Durable clearance of hepatitis B virus after allogeneic blood stem cell transplantation by adoptive immunity transfer and antiviral chemotherapy

Pediatric Infectious Disease Journal

Volumn 22, Issue 8, 2003, Pages 753-755

  Groll, Andreas H ^a   Baumann Köhler, Margit ^a   Storkebaum, Beate ^a   Kühn, Joachim ^a   Jürgens, Heribert ^a   Vormoor, Josef ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Hepatitis B; Immunity transfer; Lamivudine; Marrow transplantation

Indexed keywords

CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; IMMUNOGLOBULIN; LAMIVUDINE; METHOTREXATE; TIOGUANINE; VALACICLOVIR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUTOGRAFT; CASE REPORT; CELLULAR IMMUNITY; CLINICAL FEATURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SCHOOL CHILD; STEM CELL TRANSPLANTATION; VIRUS CARRIER; VIRUS EXCRETION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0041736117     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000078161.13315.cc     Document Type: Article

References (24)

1. Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 1997;19:795-9.
2. Chen PM, Chiou TJ, Fan FS, et al. Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation 1999;67: 1425-33.
3. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999;17:394-8.
4. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999;93:1127-36.
5. Locasciulli A, Bacigalupo A, Van Lint MT, et al. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases. Bone Marrow Transplant 1990;6:25-9.
6. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7.
7. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347: 168-74.
8. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-9.
9. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-30.
10. Lau GK, Liang R, Lee CK, et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. J Infect Dis 1998; 178:1585-91.
11. Ilan Y, Nagler A, Zeira E, Adler R, Slavin S, Shouval D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant 2000;26:633-8.
12. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996;97:1655-65.
13. Brugger SA, Oesterreicher C, Hofmann H, et al. Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet 1997;349:996-7.
14. Lau GK, Liang R, Lee CK, Lim WL. Is vaccination of donor adequate for clearance of hepatitis B virus after bone-marrow transplantation? Lancet 1997;349:1626-7.
15. Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614-24.
16. Keam SJ, Scott LJ. Lamivudine: in children and adolescents with chronic hepatitis B virus infection. Paediatr Drugs 2002;4:687-94.
17. Jonas MM, Kelly DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
18. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32: 828-34.
19. Hashino S, Nozawa A, Izumiyama K, et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002;29:361-3.
20. Seth P, Alrajhi AA, Kagevi I, et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002;30:189-94.
21. Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol 2001;15:599-603.
22. Lau GK, Wu PC, Liang R, Yuen ST, Lim WL. Persistence of hepatic hepatitis B virus after serological clearance of HbsAg with autologous peripheral stem cell transplantation. J Clin Pathol 1997;50:706-8.
23. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;93:230-9.
24. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.